Effect of Background Diuretic Therapy on the Clinical Efficacy of SGLT2 Inhibitors in Patients of Heart Failure with Reduced Ejection Fraction: Current Evidence

Abstract

Sodium-glucose cotransporter-2 (SGLT2) inhibitors are a fundamental therapy for heart failure with reduced ejection fraction
(HFrEF). The clinical efficacy of SGLT2 inhibitors in the presence of background diuretic therapy has been questioned, mainly
because of the overlapping diuretic mechanism of action. However, recently, data analysis from two landmark trials, DELIVER
and EMPEROR-Reduced, has attempted to settle this question. Both analyses demonstrate a consistent benefit of SGLT2
inhibitors across a wide range of background diuretic therapy. This brief communication sheds light on the key findings from
these scientific studies